Page last updated: 2024-10-25

deferiprone and Multiple System Atrophy

deferiprone has been researched along with Multiple System Atrophy in 1 studies

Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.

Multiple System Atrophy: A syndrome complex composed of three conditions which represent clinical variants of the same disease process: STRIATONIGRAL DEGENERATION; SHY-DRAGER SYNDROME; and the sporadic form of OLIVOPONTOCEREBELLAR ATROPHIES. Clinical features include autonomic, cerebellar, and basal ganglia dysfunction. Pathologic examination reveals atrophy of the basal ganglia, cerebellum, pons, and medulla, with prominent loss of autonomic neurons in the brain stem and spinal cord. (From Adams et al., Principles of Neurology, 6th ed, p1076; Baillieres Clin Neurol 1997 Apr;6(1):187-204; Med Clin North Am 1999 Mar;83(2):381-92)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Shukla, JJ1
Stefanova, N1
Bush, AI1
McColl, G1
Finkelstein, DI1
McAllum, EJ1

Other Studies

1 other study available for deferiprone and Multiple System Atrophy

ArticleYear
Therapeutic potential of iron modulating drugs in a mouse model of multiple system atrophy.
    Neurobiology of disease, 2021, Volume: 159

    Topics: alpha-Synuclein; Animals; Brain; Cerebellum; Ceruloplasmin; Copper; Deferiprone; Disease Models, Ani

2021